Abstracts Archive - Page 1784 of 2607 - ACR Meeting Abstracts

Abstract Number: 2779 • 2016 ACR/ARHP Annual Meeting
Better Health-Related Quality of Life and Work Capacity in Patients Achieving Inactive Disease and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis
Maxime Dougados¹, Desiree van der Heijde², Wen-Chan Tsai³, Diego Saaibi⁴, Randi Bonin⁵, Lisa Marshall⁶, Heather Jones⁷, Ronald Pedersen⁸, Bonnie Vlahos⁹ and Miriam Tarallo¹⁰, ¹Rheumatology, Paris Descartes University, Paris, France, ²Leiden University Medical Center, Leiden, Netherlands, ³Kaohsiung Medical University, Kaohsiung City, Taiwan, ⁴MEDICITY S.A.S, Bucaramanga, Colombia, ⁵Clinical Affairs, Pfizer, Collegeville, PA, ⁶Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁷Inflammation & Immunology, Pfizer, Collegeville, PA, ⁸Department of Biostatistics, Pfizer, Collegeville, PA, ⁹GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ¹⁰GHV, Pfizer, Rome, Italy
Background/Purpose: Few studies have evaluated the relationship between disease activity/clinical response and patient-reported outcomes (PROs) of pain, fatigue, health-related quality of life (HRQoL), and work…
Abstract Number: 2780 • 2016 ACR/ARHP Annual Meeting
A Modification of the Psoriatic Arthritis Disease Activity Score (mPASDAS) Using SF-12 As a Measure of Quality of Life
Matthew Got¹, Suzanne Li², Anthony V. Perruccio^3,4, Dafna D Gladman¹ and Vinod Chandran⁵, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The Psoriatic Arthritis Disease Activity Score (PASDAS) is a newly developed composite disease activity measure that summarizes psoriatic arthritis (PsA) disease activity with a…
Abstract Number: 2781 • 2016 ACR/ARHP Annual Meeting
Immunization with ApoB100 Peptide Vaccine Reduces Atherosclerosis Development in a Mouse Model of Systemic Lupus Erythematosus
Ingrid Yao-Mattisson, Maria Wigren, Gunilla Nordin Fredrikson and Jan Nilsson, Lund University, Malmö, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by impaired self-tolerance causing damage to multiple organs including the cardiovascular system. Current therapies do…
Abstract Number: 2782 • 2016 ACR/ARHP Annual Meeting
Bortezomib Treatment Prevents Glomerulosclerosis Associated with Lupus Nephritis in a Murine Model through Suppressive Effects on the Immune and Renin-Angiotensin Systems
Kazuhisa Nozawa¹, Yuko Matsuki², Ken Yamaji³, Naoto Tamura⁴ and Yoshinari Takasaki³, ¹2-1-1 Hongo Bunkyo-ku, Juntendo University, Tokyo, Japan, ²Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Rheumatology, Juntendo University, Tokyo, Japan
Background/Purpose: Lupus nephritis (LN) is one of the main causes of morbidity and mortality in SLE. Although a combination therapy using steroids and immunosuppressant…
Abstract Number: 2783 • 2016 ACR/ARHP Annual Meeting
Human Mesenchymal Stem Cells from Different Tissues Exert Distinct Therapeutic Effect on Systemic Lupus Erythematosus
Xiaojun Tang¹, Zhuoya Zhang² and Lingyun Sun¹, ¹Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Previous clinical data has shown that transplantation of umbilical cord mesenchymal stem cells (UC-MSCs) could effectively alleviate the disease symptoms in both patients with…
Abstract Number: 2784 • 2016 ACR/ARHP Annual Meeting
Mesenchymal Stem Cells Ameliorate Lupus By Promoting T Cell Apoptosis Via Bcl-2/Bim Independent Pathway in MRL/Lpr Mice
Saisai Huang¹, Dandan Wang² and Lingyun Sun¹, ¹Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology and immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease, involving in dysfunction of many organs. The abnormality of apoptosis plays an important role in…
Abstract Number: 2785 • 2016 ACR/ARHP Annual Meeting
Translatable in Vitro Immunocyte Functional Measures of CC-292 and CC-90008 Inhibitors of the Bruton’s Tyrosine Kinase (Btk)/Tec Family and the Pathology Observed in the MLR/Lpr Mouse Model of Systemic Lupus Erythematosus (SLE)
Garth Ringheim¹, Jolanta Kosek², Lori Capone³, Mary Adams^4,5, Eun Mi Hur⁴ and Peter H. Schafer⁵, ¹86 Morris Avenue, Celgene Corporation, Summit, NJ, ²Translational Development, Celgene Corporation, Summit, NJ, ³Celgene Corporation, Summit, NJ, ⁴Inflammation and Immunology Translational Development, Celgene Corporation, Summit, NJ, ⁵Department of Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose: CC-292 and CC-90008 are covalent Btk/Tec family kinase inhibitors that block Btk activity by binding with high affinity to the adenosine triphosphate (ATP) binding…
Abstract Number: 2786 • 2016 ACR/ARHP Annual Meeting
The Janus Kinase Inhibitor Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction
Yasuko Furumoto¹, Carolyne K. Smith², Luz P. Blanco³, Wanxia L. Tsai⁴, Wenpu Zhao⁵, Victoria Hoffmann⁶, Seth Thacker⁷, Giuseppe Sciumè⁸, Leti Nuñez¹, Alan Remaley⁹, John J O'Shea¹⁰, Mariana Kaplan¹¹ and Massimo G. Gadina¹², ¹NIAMS NIH, Translational Immunology Section, Office of Science and Technology, Bethesda, MD, ²Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁵NIAMS NIH, Systemic Autoimmunity Branch, Bethesda, MD, ⁶Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, ⁷NHLBI NIH, Lipoprotein Metabolism Section, Bethesda, MD, ⁸NIAMS NIH, Molecular Immunology and Inflammation Branch, Bethesda, MD, ⁹NHLBI, National Institutes of Health, Bethesda, MD, ¹⁰NIAMS NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ¹¹NIAMS/NIH, Bethesda, MD, ¹²Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Dysregulation of innate and adaptive immune responses contributes to the pathogenesis of systemic lupus erythematosus (SLE) and its associated premature vascular damage. To date,…
Abstract Number: 2787 • 2016 ACR/ARHP Annual Meeting
Bortezomib Treatment Induces Higher Mortality Rate in Lupus Model Mice with High Disease Activity
Hiroshi Fujii¹, Tomoko Ikeda¹, Masato Nose², Tomoyuki Muto³, Kanae Akita¹, Yukiko Kamogawa¹, Tsuyoshi Shirai¹, Yuko Shirota¹, Tomonori Ishii⁴ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Institute for Promotion of Advanced Science and Technology, Ehime University, Matsuyama, Japan, ³Tohoku University Graduate School of Medicine, Sendai, Japan, ⁴Tohoku University Hospital, Senndai, Japan
Background/Purpose: SLE is a chronic inflammatory disease triggered by the deposition of autoantibodies. One of the goals for SLE therapy is to suppress the production…
Abstract Number: 2788 • 2016 ACR/ARHP Annual Meeting
Suppression of IL-1 Signaling Ameliorates Dermatitis in a Murine Model of Systemic Lupus Erythematosus
Jeremy Tilstra¹, Sheldon Bastacky² and Mark Shlomchik³, ¹Rheumatology, Univ of Pittsburgh Medical Center, Pittsburgh, PA, ²Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a prototypical autoimmune disease defined by autoantibody production, immune dysregulation, and end-organ damage. Our laboratory previously showed that MyD88,…
Abstract Number: 2789 • 2016 ACR/ARHP Annual Meeting
Novel Glucocorticoid Prodrug Effectively Attenuates Late Stage Lupus Nephritis with Improved Safety Profile
Xiaobei Wang¹, Zhenshan Jia², Yangsheng Yu³, Kaihong Su³, James R. O'Dell⁴ and Dong Wang⁵, ¹Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE). Glucocorticoids (GCs) are recommended by ACR as one of the first line…
Abstract Number: 2790 • 2016 ACR/ARHP Annual Meeting
Selective Disruption of Estrogen Receptor Alpha Expression in Dendritic Cells of Lupus-Prone Mice Results in Increased Female-Specific Death
Melissa A. Cunningham¹, Jena R. Wirth², Jackie G. Eudaly² and Gary S. Gilkeson³, ¹Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ²Med/Rheumatology, Medical University of South Carolina, Charleston, SC, ³Department of Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: SLE is a disease that disproportionately affects females. The etiology of the sex bias in this disease is unclear. We previously showed that a…
Abstract Number: 2791 • 2016 ACR/ARHP Annual Meeting
Targeting Micro-RNAs Derived from Extracellular Vesicles to Inhibit of TLR7 and TLR8 Signaling Suppresses Inflammation in a Novel Human-Mouse Chimeric Model of Systemic Lupus Erythematosus
Nicholas A. Young¹, Giancarlo R. Valiente², Holly Steigelman³, Jeffrey Hampton⁴ and Wael N. Jarjour⁵, ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Rheumatology & Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University, Columbus, OH, ⁴Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Department of Rheumatology/Medicine, Ohio State University, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease displaying a heavy female predominance during reproductive years. We have previously shown that toll-like receptor…
Abstract Number: 2792 • 2016 ACR/ARHP Annual Meeting
Hyperhomocysteinemia in SLE
Michelle Petri¹ and Wei Fu², ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hyperhomocysteinemia has been correlated with the occurrence of blood clots, heart attacks and strokes. We investigated the association of the Hyperhomocysteinemia with other clinical…
Abstract Number: 2793 • 2016 ACR/ARHP Annual Meeting
The Predictors of Sustained Complete Remission in Lupus Nephritis
Rattapol Pakchotanon¹, Dafna D. Gladman², Jiandong Su² and Murray Urowitz³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Sustained complete remission is an independent predictor of good long term prognosis in lupus nephritis (LN). We aimed to examine the predictors of sustained…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].